Scarica l'app Stockscreener
92.41
5.10%
-4.97
Dopo l'orario di chiusura:
93.88
1.47
+1.59%
Precedente Chiudi:
$97.38
Aprire:
$98.3
Volume 24 ore:
224.51K
Relative Volume:
0.90
Capitalizzazione di mercato:
$1.09B
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-7.85%
1M Prestazione:
-6.65%
6M Prestazione:
+258.18%
1 anno Prestazione:
+548.49%
Intervallo 1D:
$91.90
$103.14
Intervallo di 1 settimana:
$82.38
$103.14
Portata 52W:
$12.02
$114.69
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Nome
Palvella Therapeutics Inc
Settore
Industria
Telefono
(484) 253-1461
Indirizzo
353 W. LANCASTER AVENUE, WAYNE
Confronta PVLA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
92.41 | 1.15B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-05 | Iniziato | BTIG Research | Buy |
| 2025-12-04 | Iniziato | Craig Hallum | Buy |
| 2025-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-09 | Iniziato | Oppenheimer | Outperform |
| 2025-08-06 | Iniziato | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-04-09 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-26 | Iniziato | Stifel | Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-20 | Iniziato | Canaccord Genuity | Buy |
| 2025-02-05 | Iniziato | TD Cowen | Buy |
| 2024-12-26 | Iniziato | H.C. Wainwright | Buy |
| 2024-12-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-03-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2019-07-30 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-05-14 | Iniziato | Robert W. Baird | Outperform |
| 2018-03-19 | Iniziato | Evercore ISI | Outperform |
| 2018-03-19 | Iniziato | Jefferies | Buy |
| 2018-01-16 | Reiterato | H.C. Wainwright | Buy |
| 2017-05-30 | Iniziato | Rodman & Renshaw | Buy |
| 2016-08-05 | Ripresa | ROTH Capital | Buy |
| 2015-08-12 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-07-27 | Iniziato | Oppenheimer | Outperform |
| 2015-07-22 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Palvella Therapeutics Inc Borsa (PVLA) Ultime notizie
Palvella Therapeutics provides corporate update and 2026 outlook - MarketScreener
Palvella Therapeutics Provides Corporate Update And 2026 Outlook - TradingView — Track All Markets
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies - The Manila Times
Palvella Taps Veteran Dermatology Executive to Steer Medical Affairs Push - MyChesCo
Will Palvella Therapeutics Inc. (PI6) stock benefit from commodity supercycleForecast Cut & Proven Capital Preservation Methods - ulpravda.ru
Will Palvella Therapeutics Inc. stock maintain growth storyMarket Growth Summary & Low Drawdown Investment Ideas - ulpravda.ru
Palvella Therapeutics stock maintains Buy rating at TD Cowen ahead of key trial data - Investing.com Canada
Why analysts recommend Palvella Therapeutics Inc. (PI6) stockJuly 2025 Big Picture & Advanced Swing Trade Entry Alerts - ulpravda.ru
What is the fair value of Palvella Therapeutics Inc. stock now2025 Support & Resistance & Verified Technical Trade Signals - ulpravda.ru
Will Palvella Therapeutics Inc. stock pay special dividendsPortfolio Return Report & Low Risk High Reward Ideas - ulpravda.ru
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Mizuho - Defense World
Aug Swings: Will Palvella Therapeutics Inc stock maintain growth storyJuly 2025 Technicals & High Accuracy Buy Signal Tips - moha.gov.vn
Mizuho Initiates Coverage of Palvella Therapeutics (PVLA) with Outperform Recommendation - Nasdaq
Palvella Therapeutics Appoints Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - citybiz
Palvella Therapeutics Strengthens Leadership Team with - GlobeNewswire
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs - Sahm
Mizuho initiates coverage on Palvella Therapeutics stock with Outperform rating - Investing.com UK
Palvella Therapeutics Secures New Patent for QTORIN™ Rapamycin - MSN
Earnings Recap: Will Palvella Therapeutics Inc stock pay special dividendsEarnings Recap Report & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Palvella Therapeutics (NASDAQ:PVLA) Trading Down 4.9% – What’s Next? - Defense World
Stifel Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - MSN
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 4.9%Here's What Happened - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 3.9% – Still a Buy? - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 3.9%Should You Buy? - MarketBeat
12 Overlooked Stocks That Delivered Massive Gains In 2025 - RTTNews
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1% – Should You Buy? - Defense World
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock enhance shareholder valueSector-Based Investing & Free Proven Portfolio Growth Strategies - Bollywood Helpline
Palvella Therapeutics (NASDAQ:PVLA) Shares Up 4.1%Time to Buy? - MarketBeat
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9%Here's What Happened - MarketBeat
Published on: 2025-12-23 22:49:55 - bollywoodhelpline.com
FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path - MyChesCo
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst (NASDAQ:PVLA) - Seeking Alpha
Rare disease breakthrough? Palvella reports strong phase 2 results - MSN
Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results - MyChesCo
Palvella Therapeutics stock hits 52-week high at 112.4 USD By Investing.com - Investing.com Australia
Palvella Therapeutics (NASDAQ:PVLA) Sets New 52-Week HighStill a Buy? - MarketBeat
Palvella Therapeutics stock hits 52-week high at 112.4 USD - Investing.com
Palvella Therapeutics, Inc.(NasdaqCM:PVLA) added to S&P Biotechnology Select Industry Index - marketscreener.com
Palvella Therapeutics (PVLA) Price Target Increased by 33.50% to 178.50 - Nasdaq
Adagene, Palvella gain after FDA fast track designations - MSN
High Analyst Confidence on Palvella Therapeutics (PVLA) Following Encouraging Phase 2 Data for QTORIN Rapamycin - Finviz
Will Palvella Therapeutics Inc. stock gain from lower inflation2025 Earnings Impact & Fast Gain Stock Tips - Улправда
Assessing Palvella Therapeutics’ Valuation After Its Rare Disease Momentum-Driven Surge in 2024 - Yahoo Finance
Buy Signal: Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownQuarterly Profit Report & AI Enhanced Execution Alerts - Улправда
Will Palvella Therapeutics Inc. stock attract ESG investorsTrade Signal Summary & Real-Time Market Sentiment Reports - Улправда
How Palvella Therapeutics Inc. stock trades before earningsJuly 2025 Big Picture & Fast Gaining Stock Strategy Reports - Улправда
Will Palvella Therapeutics Inc. stock continue upward momentumGlobal Markets & Weekly High Momentum Picks - Улправда
Palvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells Shares - TradingView — Track All Markets
The $100 ClubWere You Early To The Triple-Digit Rally In ABVX, NUTX, BLTE…? - RTTNews
Palvella Therapeutics Inc Azioni (PVLA) Dati Finanziari
Non sono disponibili dati finanziari per Palvella Therapeutics Inc (PVLA). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):